These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 2130768)
1. [Infiltrative and cytolytic activities of lymphokine-activated killer (LAK) cells against a human glioma mass: ultrastructural analysis using a three-dimensional multicellular spheroid model]. Iwasaki K Nihon Geka Hokan; 1990 Jan; 59(1):39-54. PubMed ID: 2130768 [TBL] [Abstract][Full Text] [Related]
2. Infiltrative and cytolytic activities of lymphokine-activated killer cells against a human glioma spheroid model. Iwasaki K; Kikuchi H; Miyatake S; Aoki T; Yamasaki T; Oda Y Cancer Res; 1990 Apr; 50(8):2429-36. PubMed ID: 2317827 [TBL] [Abstract][Full Text] [Related]
3. [Analysis of cytolytic activity and cell surface phenotypes of lymphokine activated killer cells stimulated with R-IL 2 and an anti-CD 3 antibody]. Kikuchi T; Sakai H; Nakamura N; Watanabe M; Ohno T No To Shinkei; 1990 Jun; 42(6):575-80. PubMed ID: 2119634 [TBL] [Abstract][Full Text] [Related]
4. [Isolation and expansion of glioma-infiltrating lymphocytes in vitro: an analysis of their surface phenotypes and antitumor activities]. Sawamura Y Hokkaido Igaku Zasshi; 1991 Nov; 66(6):868-78. PubMed ID: 1783372 [TBL] [Abstract][Full Text] [Related]
5. [Induction of cytotoxicity from human lymphocytes coated with bispecific antibody against human glioma cells]. Nitta T; Ishizawa A; Ito M; Sato K; Yagita H; Kumura K No Shinkei Geka; 1990 Nov; 18(11):1001-6. PubMed ID: 2247192 [TBL] [Abstract][Full Text] [Related]
6. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties. Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186 [TBL] [Abstract][Full Text] [Related]
8. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing. Wiebke EA; Custer MC; Rosenberg SA; Lotze MT J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373 [TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2. Tzeng JJ; Barth RF; Clendenon NR; Gordon WA Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388 [TBL] [Abstract][Full Text] [Related]
10. [The anti-tumor efficacy of lymphokine-activated killer (LAK) cells induced in vitro from peripheral blood lymphocytes of patients with malignant glioma]. Shimizu K; Miyao Y; Okamoto Y; Matsui Y; Ushio Y; Tsuda N; Hayakawa T; Ishida N; Mogami H No To Shinkei; 1986 Mar; 38(3):265-71. PubMed ID: 3085695 [TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors. Mitchell DH; Withrow SJ; Johnston MR; Kruse CA Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269 [TBL] [Abstract][Full Text] [Related]
12. Effect of LAK cells against three-dimensional tumor tissue. In vitro study using multi-cellular human glioma spheroids as targets. Jääskeläinen J; Kalliomäki P; Paetau A; Timonen T J Immunol; 1989 Feb; 142(3):1036-45. PubMed ID: 2783598 [TBL] [Abstract][Full Text] [Related]
13. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues. Colquhoun SD; Economou JS; Shau H; Golub SH J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167 [TBL] [Abstract][Full Text] [Related]
14. Generation of lymphokine-activated killer activity in T cells. Possible regulatory circuits. Geller RL; Smyth MJ; Strobl SL; Bach FH; Ruscetti FW; Longo DL; Ochoa AC J Immunol; 1991 May; 146(10):3280-8. PubMed ID: 1673980 [TBL] [Abstract][Full Text] [Related]
15. [Experimental studies on the antitumor activity of glioma-infiltrating lymphocytes against autologous glioma]. Li Y Zhonghua Yi Xue Za Zhi; 1992 May; 72(5):284-6, 319. PubMed ID: 1327462 [TBL] [Abstract][Full Text] [Related]
16. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2. Horton SA; Oldham RK; Yannelli JR Cancer Res; 1990 Mar; 50(6):1686-92. PubMed ID: 2306722 [TBL] [Abstract][Full Text] [Related]
17. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells. Holladay FP; Heitz T; Wood GW J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119 [TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer cells can kill target cells not only by early killing but also by late killing, and the late killing level against autotumor cell line. Komatsu F; Ishiguro K Oncol Res; 2003; 13(4):235-41. PubMed ID: 12659424 [TBL] [Abstract][Full Text] [Related]
19. Damage to multicellular human H-2 glioma spheroids incubated with LAK cells: an ultrastructural study. Jääskeläinen J; Lehtonen E; Heikkilä P; Kalliomäki P; Timonen T J Natl Cancer Inst; 1990 Mar; 82(6):497-501. PubMed ID: 2313722 [TBL] [Abstract][Full Text] [Related]
20. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples. Teichmann JV; Ludwig WD; Thiel E Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]